

Civil complaint filed against Gambro

Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that the Attorney General for the State of Michigan in the US has filed a civil complaint against Gambro's subsidiary, GAMBRO Healthcare, Inc.

The Attorney General alleges that GAMBRO Healthcare has attempted to monopolize the market for dialysis services in three counties in Michigan by employing measures which violate state antitrust laws in Michigan. This action arose out of negotiations in regard to a contract for dialysis services with a private payor.

The Attorney General asserts, among other things, that GAMBRO Healthcare has exploited its market position in the area by charging excessive prices. GAMBRO Healthcare will respond to the complaint when ongoing investigations have been completed. It is the company's policy to comply with all state and federal laws, including antitrust laws.

For further information please contact:

Bengt Mod  r, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00, +46-70-513 65 33

Tim Schoenberg, Vice President, US Investor Relations Manager, +1-949-425-2185

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is one of the leading providers of kidney dialysis services in the world. Gambro treats about 42,000 patients in 565 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis fluid. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.